Nootropics Index - Save on smarter supplements
Nootropics>Synthetic nootropics & research compounds>9-Me-BC
Synthetic nootropics & research compounds

9-Me-BC

9-Me-BC / 9-methyl-beta-carboline

9-Me-BC is 9-methyl-beta-carboline, a synthetic beta-carboline research compound. The available evidence is preclinical: dopaminergic-neuron culture work, a toxin-exposed rat model, a rat spatial-learning study, and in vitro MAO-A/MAO-B inhibition. No reliable human efficacy, pharmacokinetic, safety, or interaction studies were identified, so human risk and interaction relevance cannot be characterised from the current evidence.

DopaminergicNeurotrophic PathwaysInflammation PathwaysSyntheticMostly Animal EvidenceModerate Risk ProfileMedication Interaction Risk
Updated July 2026/6 min read/11 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

What 9-Me-BC is

1

9-Me-BC is 9-methyl-beta-carboline, a synthetic beta-carboline also listed by PubChem as 9-methylnorharmane. The research cited here is preclinical rather than human evidence.

Evidence is preclinical5
The strongest sources are cell-culture and rat studies. They explore dopaminergic neurons, inflammatory markers, neurotrophic factors, MAO inhibition, and rat spatial learning. They do not establish human focus, memory, mood, neurological, or productivity effects.
02

Names, aliases and forms

Common Name9-Me-BC
Abbreviation9mbc
Chemical Names9-methyl-beta-carboline; 9-methylnorharmane; N-methylnorharmane
Iupac Name9-methylpyrido[3,4-b]indole
Cas Number2521-07-5
Pubchem Cid164979
Molecular FormulaC12H10N2
InchikeyMABOIYXDALNSES-UHFFFAOYSA-N
03

Mechanisms of action

Dopamine and neurotrophic signals

3

Cell studies report increased tyrosine-hydroxylase markers, neurite outgrowth, neurotrophic-factor expression, anti-inflammatory signals, and lower alpha-synuclein protein in culture. These are research mechanisms, not clinical outcomes.

MAO-A and MAO-B inhibition

6

A 2020 study reported in vitro inhibition of MAO-A and MAO-B by 9-Me-BC. That may help explain dopamine-related findings, but it also creates plausible MAOI-like interaction risk that has not been mapped in humans.

04

Potential effects and evidence map

9-Me-BC has preclinical literature reporting dopaminergic-neuron culture findings, signals in a toxin-exposed rat model, rat spatial-learning changes, astrocyte neurotrophic-factor expression, and in vitro MAO-A/MAO-B inhibition. These findings are hypothesis-generating only. No reliable human dosing, pharmacokinetic, efficacy, tolerability, long-term-safety, or interaction studies were identified, so product listings should not be interpreted as clinical guidance.

Effect domainMagnitudeGrade
Cellular / long-term brain support3
UnknownConfidence: Low

Preclinical cell and rat models suggest dopaminergic neurotrophic and anti-inflammatory activity, but no human neuroprotection outcome is established.

Note Do not treat anti-Parkinson hypotheses as clinical evidence.

1/5
D
Memory / learning5
UnknownConfidence: Low

A rat spatial-learning study reported cognitive-task changes after 10 days, but reliable human memory or learning evidence was not found.

Note Animal cognition finding only.

1/5
D
Motivation / drive6
UnknownConfidence: Low

Dopamine-related mechanisms may explain marketing interest, but human motivation, drive, focus, or mood effects are untested.

Note Mechanistic dopamine language must stay preclinical.

1/5
D
05

Typical dosages and timing

Active listing1115 mg/capsule

This is retailer listing context, not a validated human dose or a user protocol.

06

Timing & effect horizon

Effect horizonUnknown
Unknown
No human timing data10

Reliable human onset, duration, half life, washout, tolerance, and cycling data were not found. Rat and cell-study exposure windows should not be used to infer human timing.

07

Safety, side effects and risk profile

Mouse toxicology signal needs context7
A 7-day mouse study of 9-methyl-norharman reported movement slowing and lower dopamine and tyrosine-hydroxylase markers. The study also implicated a different di-N-methylated metabolite, so it does not establish human effects or risk from an oral product listing.
Photoexcited DNA-damage finding is preclinical9
A laboratory study found DNA-damage mechanisms after UVA excitation of 9-methyl-norharmane. This does not establish phototoxicity, skin effects, or risk from normal human use.
Interaction risk6
Confidence: Low

9-Me-BC inhibits MAO-A and MAO-B in vitro; its interaction relevance in people has not been studied.

Note This low-confidence row flags an evidence gap and general MAOI context; it does not establish a human interaction magnitude or threshold.

2/5
D
Cardiovascular caution8
Confidence: Low

General MAOI pharmacology raises a theoretical blood-pressure concern, but no human 9-Me-BC cardiovascular dataset was identified.

Note This is indirect MAOI context, not a demonstrated 9-Me-BC effect.

1/5
E
Overstimulation / insomnia6
Confidence: Low

Dopamine- and MAO-related mechanisms make activation-related effects possible, but human frequency and severity are unknown.

Note Preclinical mechanism only; no human adverse-effect rate was identified.

1/5
E
Evidence uncertainty5
Confidence: High

No reliable human efficacy, pharmacokinetic, tolerability, long-term-safety, reproductive-safety, or dose-ranging studies were identified; preclinical models also report conflicting signals.

Note A 7-day mouse study of 9-methyl-norharman reported movement slowing and lower dopamine/tyrosine-hydroxylase markers, while other models report different findings. Neither establishes human risk for typical oral use.

3/5
D
Human safety is not established10

The cited evidence base contains no reliable human safety trial, adverse-event rate, reproductive-safety dataset, liver/kidney monitoring dataset, or long-term follow-up. It cannot characterise safety for typical human oral use.

Beta-carboline context cuts both ways2

The 9-Me-BC literature itself notes that some beta-carbolines can be neurotoxic while 9-Me-BC showed protective/restorative signals in models. That contrast is not enough to establish human safety.

08

Interactions and cautions

Potential MAOI-like interaction concern8

9-Me-BC inhibited MAO-A and MAO-B in vitro. The interaction relevance in people is unknown. General MAOI sources identify serotonergic medicines, stimulants, dextromethorphan, certain opioids, bupropion, mirtazapine, St. John wort, sympathomimetics, and tyramine-rich foods as interaction contexts; this analogy does not establish the same risk or threshold for 9-Me-BC.

Tyramine and blood-pressure uncertainty8

General MAOI guidance describes tyramine-related blood-pressure risk. No human 9-Me-BC food, pressor-agent, or cardiovascular interaction study was identified, so that evidence cannot define a 9-Me-BC threshold.

Psychiatric medication context is unstudied6

No human data establish 9-Me-BC safety alongside psychiatric medication or in people with mania, psychosis, panic, anxiety, insomnia, or impulsivity histories. Dopamine- and monoamine-related mechanisms are not a substitute for that evidence.

09

Practical buying and quality notes

  • For like-for-like capsule comparisons, verify chemical name, CAS 2521-07-5, PubChem CID 164979, lot-specific assay method, certificate of analysis, impurities, residual solvents, capsule fill accuracy, storage, and expiration. A listed price or capsule amount does not establish identity, safety, or human-dose validity.1
  • The current inventory contains one active capsule offer. A retailer listing does not establish additional forms, product identity, safety, or a human dosing standard.11
10

FAQ

What is 9-Me-BC?

1

9-Me-BC is 9-methyl-beta-carboline, a synthetic beta-carboline researched mainly in dopaminergic-neuron culture, toxin-exposed rat, MAO-inhibition, and rat cognition studies.

What is the 9-Me-BC dose?

11

The displayed capsule amount is retailer context only. A validated human dose was not identified.

Does 9-Me-BC improve memory?

5

A rat study reported spatial-learning changes after 10 days with hippocampal dopamine and dendritic/spine changes. This does not establish human memory, focus, or productivity effects.

Why are interactions emphasized?

8

Lab work, rather than a human study, is the cited source of MAO-A/MAO-B inhibition. General MAOI pharmacology includes important interaction contexts, but it cannot determine their magnitude, threshold, or management for 9-Me-BC.

Which safety contexts lack human data?

10

The cited evidence base does not establish safety in pregnancy or lactation, with psychiatric or monoamine-active medicines, in cardiovascular illness, with liver/kidney impairment, or with seizure history. No human adverse-event rate or long-term follow-up was identified.

11

References

  1. PubChem. 9-Methyl-9H-pyrido[3,4-b]indole (CID 164979). Accessed 2026-07-01.
  2. Hamann J, et al. 9-Methyl-beta-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture. Neurochem Int. 2008;52(4-5):688-700.
  3. Polanski W, et al. The exceptional properties of 9-methyl-beta-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects. J Neurochem. 2010;113(6):1659-1675.
  4. Wernicke C, et al. 9-Methyl-beta-carboline has restorative effects in an animal model of Parkinson disease. Pharmacol Rep. 2010;62(1):35-53.
  5. Gruss M, et al. 9-Methyl-beta-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation. J Neurochem. 2012;121(6):924-931.
  6. Keller S, et al. 9-Methyl-beta-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes. J Neural Transm (Vienna). 2020;127(7):999-1012.
  7. Matsubara K, et al. Endogenously occurring beta-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson disease. J Neurochem. 1998;70(2):727-735.
  8. Patel P, Saadabadi A. Monoamine Oxidase Inhibitors (MAOIs). StatPearls. Last updated 2025-12-13. Accessed 2026-07-01.
  9. Vignoni M, et al. Mechanisms of DNA damage by photoexcited 9-methyl-beta-carbolines. Org Biomol Chem. 2013;11(32):5300-5309.
  10. NootropicsIndex literature search. PubMed search for 9-methyl-beta-carboline. Reviewed 2026-07-23.
  11. NootropicsIndex active inventory. One 9-Me-BC 15 mg capsule offer. Accessed 2026-07-23.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.